KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Return on Sales: 2017-2024

Historic Return on Sales for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to 43.79%.

  • Aquestive Therapeutics' Return on Sales rose 584.00% to 5.24% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.24%, marking a year-over-year increase of 584.00%. This contributed to the annual value of 43.79% for FY2024, which is 4363.00% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Return on Sales of 43.79% as of FY2024, which was down 28,043.11% from 0.16% recorded in FY2023.
  • Aquestive Therapeutics' Return on Sales' 5-year high stood at 0.16% during FY2023, with a 5-year trough of 43.79% in FY2024.
  • Over the past 3 years, Aquestive Therapeutics' median Return on Sales value was 1.14% (recorded in 2022), while the average stood at 15.03%.
  • As far as peak fluctuations go, Aquestive Therapeutics' Return on Sales surged by 1,256bps in 2021, and later tumbled by 4,363bps in 2024.
  • Aquestive Therapeutics' Return on Sales (MRY) stood at 13.95% in 2020, then soared by 90bps to 1.39% in 2021, then rose by 18bps to 1.14% in 2022, then surged by 86bps to 0.16% in 2023, then tumbled by 28,043bps to 43.79% in 2024.
  • Its last three reported values are 43.79% in FY2024, 0.16% for FY2023, and 1.14% during FY2022.